Biocept Inc (BIOC) 4.63 $BIOC
Biocept, Inc. Closes $10 Million Term Loan Facility With Oxford Finance LLC
GlobeNewswire - Wed May 07, 3:48PM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company specializing in oncology biomarker detection and monitoring through circulating tumor cells (CTCs) and cell-free circulating tumor DNA, today announced that it has closed a loan facility of up to $10 million (the "facility"
with Oxford Finance LLC ("Oxford" . The facility will support working capital and general corporate needs and augments the Company's financial flexibility to pursue growth opportunities.
Nasdaq stocks posting largest percentage increases
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Biocept Launches Clinical Research Services for Biomarker Detection in Circulating Tumor DNA
GlobeNewswire - Mon Apr 28, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company specializing in oncology biomarker detection and monitoring through circulating tumor cells (CTCs) and cell-free circulating tumor DNA, today announced the launch of its clinical research services offering.
Biocept Appoints Commercialization Leader to Implement Global Diagnostic Sales Program
GlobeNewswire - Mon Mar 24, 10:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) and biomarker analysis, today announced that it has appointed Raaj Trivedi as Vice President - Commercial Operations.
Biocept, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today that the Company's President and Chief Executive Officer, Michael Nall will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
10-Q: MALVERN BANCORP, INC.
Edgar Online - Wed Feb 12, 3:35PM CST
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations
Biocept, Inc. Announces Closing of Initial Public Offering
GlobeNewswire - Mon Feb 10, 5:06PM CST
Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today the closing of its previously announced initial public offering of 1,900,000 shares of common stock, at a public offering price of $10.00 per share. The gross proceeds to Biocept from the offering were $19,000,000, before deducting underwriting discounts and commissions and other offering expenses payable by Biocept.
IPO roundup: 5 companies go public Wednesday
By The Associated Press - AP - Wed Feb 05, 4:34PM CST
Five companies made their stock market debuts Wednesday. They are the latest initial public offerings to hit the market in 2014 after high demand for IPOs in the last year as stock markets rose.
Biocept, Inc. Announces Pricing of Initial Public Offering
GlobeNewswire - Tue Feb 04, 9:49PM CST
Biocept, Inc., an oncology diagnostics company focused on improving individual patient treatment, today announced the pricing of its initial public offering of 1,900,000 shares of its common stock offered at a price to the public of $10.00 per share. The gross proceeds to Biocept from the initial public offering are expected to be $19,000,000, before underwriting discounts and commissions and other offering expenses. Biocept has granted the representative of the underwriters a 45-day option to purchase up to 285,000 additional shares of common stock to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Capital Market under the symbol "BIOC" on February 5, 2014 and the offering is expected to close on February 10, 2014, subject to customary closing conditions.
Zimmer Holdings, Inc. Reports Fourth Quarter and 2013 Financial Results
PR Newswire - Thu Jan 30, 6:30AM CST
Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today reported financial results for the quarter and year ended December 31, 2013. The Company reported fourth quarter net sales of $1.24 billion, an increase of 5.1% reported and 6.6% constant currency over the fourth quarter of 2012. Diluted earnings per share for the quarter were $1.36 reported and $1.66 adjusted, an increase of 9.9% adjusted over the prior year period. Full year net sales were $4.62 billion, an increase of 3.4% reported and 4.9% constant currency over the prior year. Diluted earnings per share for the year were $4.43 reported and $5.75 adjusted, an increase of 8.5% adjusted over the prior year.
Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
PR Newswire - Wed May 01, 3:01PM CDT
Covance Inc. (NYSE: CVD) today reported results for its first quarter ended March 31, 2013. Net revenue was $580 million, representing 9.3% growth from the first quarter of 2012. On a GAAP basis, the company reported earnings of $0.86 per diluted share in the first quarter. Excluding a gain on the sale of our investment in BioClinica, Inc. of $15.7 million and restructuring costs totaling $6.2 million, the company reported earnings per diluted share of $0.75, up 24.7% over the first quarter of 2012.
BioClinica, Inc. to Demonstrate Technology-Enhanced Capabilities at Upcoming Global Industry Events
PR Newswire - Wed Apr 03, 7:00AM CDT
BioClinica®, Inc. a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in, and speak at several upcoming industry conferences in April, May, and June. BioClinica experts will discuss industry trends and demonstrate the company's suite of technologies and solutions. The conferences include:
BioClinica and CoreLab Partners Are One
Business Wire - Thu Mar 14, 6:00AM CDT
BioClinica(R), Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced today that JLL Partners and Ampersand Capital Partners, two leading middle market private equity firms, have completed their acquisition of BioClinica and CoreLab Partners and have combined the two companies under the name BioClinica.
BioClinica, Inc. and JLL Partners, Inc. Announce Successful Completion of Tender Offer
Business Wire - Tue Mar 12, 6:00AM CDT
BioClinica(R), Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, and JLL Partners, Inc. ("JLL" , a leading private equity investment firm, today announced the successful completion of the tender offer by BC Acquisition Corp. ("Purchaser" , a wholly-owned subsidiary of BioCore Holdings, Inc. ("Parent" , each of which is an affiliate of JLL, for all of the outstanding shares of common stock of BioClinica. Purchaser and Parent are affiliates of JLL and one of the investment funds managed by JLL, JLL Partners Fund VI, L.P. (the "Sponsor" .
Medtentia International and clinicalprojects international Tap BioClinica for Express EDC, Data Management, and Centralized Imaging Reads
Business Wire - Mon Mar 04, 3:00AM CST
BioClinica(R), Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced an agreement for BioClinica Express EDC, data management, and imaging core lab services with Finnish company Medtentia International, in partnership with the contract research organization (CRO) clinicalprojects international (CPI). Medtentia International Ltd. is a medical technology company which develops solutions for mitral valve repair based on its proprietary helix ring concept. Medtentia's technology has the potential to reduce the invasiveness, operation time and morbidity associated with mitral valve repair operations.
BioClinica, Inc. and JLL Partners, Inc. Announce Early Termination of Hart-Scott-Rodino Act Waiting Period
Business Wire - Thu Feb 21, 3:30PM CST
BioClinica(R), Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, and JLL Partners, Inc., a leading private equity investment firm, today announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has been granted in connection with the pending acquisition by BC Acquisition Corp., a wholly-owned subsidiary of BioCore Holdings, Inc., of BioClinica for $7.25 per share in cash. As previously announced, JLL is accomplishing the acquisition of BioClinica through a tender offer, which commenced on February 11, 2013 and is scheduled to expire at 12:00 midnight, New York City time, at the end of Monday, March 11, 2013, unless the tender offer is extended. The tender offer is being conducted on the terms and subject to the conditions described in the Offer to Purchase, dated February 11, 2013, and the related Letter of T
Clinical Trial Management Systems (CTMS) - 2012 Global Strategic Business Report Profiles 75 Players
M2 - Mon Feb 18, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5bjt6/clinical_trial) has announced the addition of the updated "Clinical Trial Management Systems (CTMS) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Trial Management Systems (CTMS) in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 75 companies including many key and niche players. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Companies Mentioned - Aris Global, LLC (US) - BioClinica, Inc. (US) - Bio-Optronics, Inc. (US) - Clinical Force, Inc. (US) - DSG, Inc. (US) - eClinForce, Inc. (US) - eResearch Technology, Inc. (US) -
Cash Tender Offer to Acquire BioClinica, Inc. at $7.25 Per Share Commenced by an Affiliate of JLL Partners, Inc.
Business Wire - Mon Feb 11, 6:30AM CST
BioClinica(R), Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions and JLL Partners, Inc. ("JLL" , a leading private equity investment firm, announced today that BC Acquisition Corp. ("Purchaser" , which is a wholly-owned subsidiary of BioCore Holdings, Inc. ("Parent" , each of which is an affiliate of JLL, has commenced a tender offer for all outstanding shares of BioClinica at a price of $7.25 per share net to the seller in cash. The offer is being made pursuant to a definitive merger agreement pursuant to which Parent will acquire BioClinica. Parent and Purchaser are affiliates of JLL Partners Fund VI, L.P. (the "Sponsor" , which is a private equity investment fund managed by JLL.
Biocept, Inc. Closes $10 Million Term Loan Facility With Oxford Finance LLC
GlobeNewswire - Wed May 07, 3:48PM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company specializing in oncology biomarker detection and monitoring through circulating tumor cells (CTCs) and cell-free circulating tumor DNA, today announced that it has closed a loan facility of up to $10 million (the "facility"
with Oxford Finance LLC ("Oxford" . The facility will support working capital and general corporate needs and augments the Company's financial flexibility to pursue growth opportunities. Nasdaq stocks posting largest percentage increases
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Biocept Launches Clinical Research Services for Biomarker Detection in Circulating Tumor DNA
GlobeNewswire - Mon Apr 28, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company specializing in oncology biomarker detection and monitoring through circulating tumor cells (CTCs) and cell-free circulating tumor DNA, today announced the launch of its clinical research services offering.
Biocept Appoints Commercialization Leader to Implement Global Diagnostic Sales Program
GlobeNewswire - Mon Mar 24, 10:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) and biomarker analysis, today announced that it has appointed Raaj Trivedi as Vice President - Commercial Operations.
Biocept, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today that the Company's President and Chief Executive Officer, Michael Nall will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
10-Q: MALVERN BANCORP, INC.
Edgar Online - Wed Feb 12, 3:35PM CST
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations
Biocept, Inc. Announces Closing of Initial Public Offering
GlobeNewswire - Mon Feb 10, 5:06PM CST
Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today the closing of its previously announced initial public offering of 1,900,000 shares of common stock, at a public offering price of $10.00 per share. The gross proceeds to Biocept from the offering were $19,000,000, before deducting underwriting discounts and commissions and other offering expenses payable by Biocept.
IPO roundup: 5 companies go public Wednesday
By The Associated Press - AP - Wed Feb 05, 4:34PM CST
Five companies made their stock market debuts Wednesday. They are the latest initial public offerings to hit the market in 2014 after high demand for IPOs in the last year as stock markets rose.
Biocept, Inc. Announces Pricing of Initial Public Offering
GlobeNewswire - Tue Feb 04, 9:49PM CST
Biocept, Inc., an oncology diagnostics company focused on improving individual patient treatment, today announced the pricing of its initial public offering of 1,900,000 shares of its common stock offered at a price to the public of $10.00 per share. The gross proceeds to Biocept from the initial public offering are expected to be $19,000,000, before underwriting discounts and commissions and other offering expenses. Biocept has granted the representative of the underwriters a 45-day option to purchase up to 285,000 additional shares of common stock to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Capital Market under the symbol "BIOC" on February 5, 2014 and the offering is expected to close on February 10, 2014, subject to customary closing conditions.
Zimmer Holdings, Inc. Reports Fourth Quarter and 2013 Financial Results
PR Newswire - Thu Jan 30, 6:30AM CST
Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today reported financial results for the quarter and year ended December 31, 2013. The Company reported fourth quarter net sales of $1.24 billion, an increase of 5.1% reported and 6.6% constant currency over the fourth quarter of 2012. Diluted earnings per share for the quarter were $1.36 reported and $1.66 adjusted, an increase of 9.9% adjusted over the prior year period. Full year net sales were $4.62 billion, an increase of 3.4% reported and 4.9% constant currency over the prior year. Diluted earnings per share for the year were $4.43 reported and $5.75 adjusted, an increase of 8.5% adjusted over the prior year.
Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
PR Newswire - Wed May 01, 3:01PM CDT
Covance Inc. (NYSE: CVD) today reported results for its first quarter ended March 31, 2013. Net revenue was $580 million, representing 9.3% growth from the first quarter of 2012. On a GAAP basis, the company reported earnings of $0.86 per diluted share in the first quarter. Excluding a gain on the sale of our investment in BioClinica, Inc. of $15.7 million and restructuring costs totaling $6.2 million, the company reported earnings per diluted share of $0.75, up 24.7% over the first quarter of 2012.
BioClinica, Inc. to Demonstrate Technology-Enhanced Capabilities at Upcoming Global Industry Events
PR Newswire - Wed Apr 03, 7:00AM CDT
BioClinica®, Inc. a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in, and speak at several upcoming industry conferences in April, May, and June. BioClinica experts will discuss industry trends and demonstrate the company's suite of technologies and solutions. The conferences include:
BioClinica and CoreLab Partners Are One
Business Wire - Thu Mar 14, 6:00AM CDT
BioClinica(R), Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced today that JLL Partners and Ampersand Capital Partners, two leading middle market private equity firms, have completed their acquisition of BioClinica and CoreLab Partners and have combined the two companies under the name BioClinica.
BioClinica, Inc. and JLL Partners, Inc. Announce Successful Completion of Tender Offer
Business Wire - Tue Mar 12, 6:00AM CDT
BioClinica(R), Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, and JLL Partners, Inc. ("JLL"
, a leading private equity investment firm, today announced the successful completion of the tender offer by BC Acquisition Corp. ("Purchaser" , a wholly-owned subsidiary of BioCore Holdings, Inc. ("Parent" , each of which is an affiliate of JLL, for all of the outstanding shares of common stock of BioClinica. Purchaser and Parent are affiliates of JLL and one of the investment funds managed by JLL, JLL Partners Fund VI, L.P. (the "Sponsor" . Medtentia International and clinicalprojects international Tap BioClinica for Express EDC, Data Management, and Centralized Imaging Reads
Business Wire - Mon Mar 04, 3:00AM CST
BioClinica(R), Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced an agreement for BioClinica Express EDC, data management, and imaging core lab services with Finnish company Medtentia International, in partnership with the contract research organization (CRO) clinicalprojects international (CPI). Medtentia International Ltd. is a medical technology company which develops solutions for mitral valve repair based on its proprietary helix ring concept. Medtentia's technology has the potential to reduce the invasiveness, operation time and morbidity associated with mitral valve repair operations.
BioClinica, Inc. and JLL Partners, Inc. Announce Early Termination of Hart-Scott-Rodino Act Waiting Period
Business Wire - Thu Feb 21, 3:30PM CST
BioClinica(R), Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, and JLL Partners, Inc., a leading private equity investment firm, today announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has been granted in connection with the pending acquisition by BC Acquisition Corp., a wholly-owned subsidiary of BioCore Holdings, Inc., of BioClinica for $7.25 per share in cash. As previously announced, JLL is accomplishing the acquisition of BioClinica through a tender offer, which commenced on February 11, 2013 and is scheduled to expire at 12:00 midnight, New York City time, at the end of Monday, March 11, 2013, unless the tender offer is extended. The tender offer is being conducted on the terms and subject to the conditions described in the Offer to Purchase, dated February 11, 2013, and the related Letter of T
Clinical Trial Management Systems (CTMS) - 2012 Global Strategic Business Report Profiles 75 Players
M2 - Mon Feb 18, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5bjt6/clinical_trial) has announced the addition of the updated "Clinical Trial Management Systems (CTMS) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Trial Management Systems (CTMS) in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 75 companies including many key and niche players. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Companies Mentioned - Aris Global, LLC (US) - BioClinica, Inc. (US) - Bio-Optronics, Inc. (US) - Clinical Force, Inc. (US) - DSG, Inc. (US) - eClinForce, Inc. (US) - eResearch Technology, Inc. (US) -
Cash Tender Offer to Acquire BioClinica, Inc. at $7.25 Per Share Commenced by an Affiliate of JLL Partners, Inc.
Business Wire - Mon Feb 11, 6:30AM CST
BioClinica(R), Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions and JLL Partners, Inc. ("JLL"
, a leading private equity investment firm, announced today that BC Acquisition Corp. ("Purchaser" , which is a wholly-owned subsidiary of BioCore Holdings, Inc. ("Parent" , each of which is an affiliate of JLL, has commenced a tender offer for all outstanding shares of BioClinica at a price of $7.25 per share net to the seller in cash. The offer is being made pursuant to a definitive merger agreement pursuant to which Parent will acquire BioClinica. Parent and Purchaser are affiliates of JLL Partners Fund VI, L.P. (the "Sponsor" , which is a private equity investment fund managed by JLL. 
